Wang Xiaolin 4
4 · Revolution Medicines, Inc. · Filed Mar 19, 2026
Research Summary
AI-generated summary of this filing
Revolution Medicines (RVMD) EVP Wang Xiaolin Sells Shares
What Happened
- Wang Xiaolin, EVP of Clinical Development at Revolution Medicines, sold 2,010 shares on 2026-03-17 at $99.48 per share, generating proceeds of $199,956. The sale is reported as an open‑market or private sale and is coded as a sale (S) on the Form 4.
Key Details
- Transaction date and price: 2026-03-17 at $99.48 per share.
- Shares sold / proceeds: 2,010 shares sold for $199,956 total.
- Ownership after transaction: Reported beneficial ownership disclosure includes 48,700 RSUs (footnote), as noted on the filing.
- Notable footnotes: (F1) Sale executed pursuant to a Rule 10b5-1 plan adopted 2025-11-17 to satisfy tax withholding on RSU vesting after 2025-12-15; (F2) the reported holding includes 48,700 RSUs.
- Filing timeliness: Form filed 2026-03-19 for a 2026-03-17 transaction (filed within the required Form 4 timeframe).
Context
- The sale was made under a pre-established 10b5-1 plan to cover tax withholding tied to RSU vesting, which is a common, tax-driven reason for insider sales and not necessarily a signal of management’s view on the stock. Purchases tend to be more indicative of bullish insider sentiment.
Insider Transaction Report
Form 4
Wang Xiaolin
See Remarks
Transactions
- Sale
Common Stock
[F1][F2]2026-03-17$99.48/sh−2,010$199,956→ 116,063 total
Footnotes (2)
- [F1]Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on November 17, 2025 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after December 15, 2025.
- [F2]Includes 48,700 RSUs.
Signature
/s/ Jack Anders, as Attorney-in-fact for Xiaolin Wang|2026-03-19